Form 8-K - Current report:
SEC Accession No. 0001558370-24-009853
Filing Date
2024-07-16
Accepted
2024-07-16 16:30:16
Documents
15
Period of Report
2024-07-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20240716x8k.htm   iXBRL 8-K 41269
2 EX-99.1 acrs-20240716xex99d1.htm EX-99.1 10546
3 GRAPHIC acrs-20240716xex99d1001.jpg GRAPHIC 11104
  Complete submission text file 0001558370-24-009853.txt   192845

Data Files

Seq Description Document Type Size
4 EX-101.SCH acrs-20240716.xsd EX-101.SCH 3135
5 EX-101.LAB acrs-20240716_lab.xml EX-101.LAB 15916
6 EX-101.PRE acrs-20240716_pre.xml EX-101.PRE 10223
17 EXTRACTED XBRL INSTANCE DOCUMENT acrs-20240716x8k_htm.xml XML 4840
Mailing Address 701 LEE ROAD SUITE 103 WAYNE PA 19087
Business Address 701 LEE ROAD SUITE 103 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 241119972
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)